Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Azenta, Inc. (NASDAQ:AZTA). In a filing disclosed on February 13th, the Representative disclosed that they had bought between $1,001 and $15,000 in Azenta stock on January 15th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.
Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):
- Purchased $1,001 – $15,000 in shares of Hermès International Société en commandite par actions (OTCMKTS:HESAF) on 2/3/2026.
- Purchased $1,001 – $15,000 in shares of Tencent (OTC:TCTZF) on 2/3/2026.
- Purchased $1,001 – $15,000 in shares of Xiaomi (OTCMKTS:XIACF) on 2/3/2026.
- Purchased $1,001 – $15,000 in shares of Mitsubishi Heavy Industries (OTCMKTS:MHVYF) on 2/3/2026.
- Purchased $1,001 – $15,000 in shares of Banco Santander (NYSE:SAN) on 2/3/2026.
- Purchased $1,001 – $15,000 in shares of Leonardo (OTCMKTS:FINMF) on 2/3/2026.
- Purchased $1,001 – $15,000 in shares of Costco Wholesale (NASDAQ:COST) on 1/30/2026.
- Purchased $1,001 – $15,000 in shares of Transdigm Group (NYSE:TDG) on 1/30/2026.
- Purchased $1,001 – $15,000 in shares of Cloudflare (NYSE:NET) on 1/30/2026.
- Purchased $1,001 – $15,000 in shares of AutoZone (NYSE:AZO) on 1/30/2026.
Azenta Trading Down 1.3%
Shares of Azenta stock traded down $0.39 on Friday, hitting $29.28. 569,769 shares of the company traded hands, compared to its average volume of 917,651. Azenta, Inc. has a 52 week low of $23.91 and a 52 week high of $47.55. The company has a market cap of $1.35 billion, a PE ratio of -21.69 and a beta of 1.35. The stock’s 50 day moving average price is $34.92 and its 200-day moving average price is $32.58.
Azenta announced that its board has authorized a share repurchase program on Wednesday, December 10th that allows the company to repurchase $250.00 million in outstanding shares. This repurchase authorization allows the company to buy up to 14.9% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Integrated Wealth Concepts LLC acquired a new stake in shares of Azenta in the first quarter valued at approximately $435,000. Millennium Management LLC grew its holdings in Azenta by 214.8% in the 1st quarter. Millennium Management LLC now owns 340,580 shares of the company’s stock valued at $11,798,000 after buying an additional 232,405 shares in the last quarter. Empowered Funds LLC increased its stake in shares of Azenta by 10.5% in the 1st quarter. Empowered Funds LLC now owns 6,482 shares of the company’s stock worth $225,000 after acquiring an additional 618 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Azenta by 17.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 201,337 shares of the company’s stock worth $6,974,000 after acquiring an additional 30,492 shares during the period. Finally, CWM LLC boosted its position in shares of Azenta by 113.5% during the 2nd quarter. CWM LLC now owns 1,898 shares of the company’s stock valued at $58,000 after acquiring an additional 1,009 shares during the last quarter. 99.08% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several equities analysts recently weighed in on AZTA shares. Raymond James Financial upped their price target on shares of Azenta from $35.00 to $45.00 and gave the company an “outperform” rating in a report on Tuesday, November 25th. Weiss Ratings restated a “sell (e+)” rating on shares of Azenta in a research note on Monday, December 22nd. Zacks Research raised Azenta from a “strong sell” rating to a “hold” rating in a report on Monday, January 26th. Jefferies Financial Group reduced their price target on Azenta from $42.00 to $40.00 and set a “buy” rating for the company in a research report on Wednesday, February 4th. Finally, Needham & Company LLC restated a “buy” rating and issued a $44.00 price objective on shares of Azenta in a research report on Wednesday, February 4th. Four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Azenta presently has an average rating of “Hold” and a consensus price target of $41.33.
Check Out Our Latest Analysis on Azenta
About Representative Cisneros
Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.
Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.
About Azenta
Azenta, Inc (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.
In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services.
Featured Stories
- Five stocks we like better than Azenta
- The gold chart Wall Street is terrified of…
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- This $15 Stock Could Go Down as the #1 Stock of 2026
- ~$1.5T SpaceX IPO: Pre-IPO Opportunity
Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.
